Nemonoxacin

Generic Name
Nemonoxacin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H25N3O4
CAS Number
378746-64-6
Unique Ingredient Identifier
P94L0PVO94
Indication

Investigated for use/treatment in bacterial infection and pneumonia.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Oral Nemonoxacin in Treating Elderly Patients With CAP

Phase 4
Completed
Conditions
Community-acquired Pneumonia
Interventions
Drug: Nemonoxacin
First Posted Date
2021-11-24
Last Posted Date
2021-11-24
Lead Sponsor
TaiGen Biotechnology Co., Ltd.
Target Recruit Count
100
Registration Number
NCT05133752
Locations
🇨🇳

Tri-Service General Hospital, Taipei, Taiwan

Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia

First Posted Date
2018-06-11
Last Posted Date
2023-02-16
Lead Sponsor
R-Pharm
Target Recruit Count
342
Registration Number
NCT03551210
Locations
🇷🇺

City clinical hospital #40, Ekaterinburg, Russian Federation

🇷🇺

Regional budget healthcare institution "Ivanovo regional clinical hospital", Ivanovo, Russian Federation

🇷🇺

City Clinical hospital n.a. V. V. Vinogradov, Moscow, Russian Federation

and more 22 locations

Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function

Phase 1
Conditions
Kidney Dysfunction
Interventions
Drug: Nemonoxacin
First Posted Date
2016-07-21
Last Posted Date
2018-04-03
Lead Sponsor
Zhejiang Medicine Co., Ltd.
Target Recruit Count
24
Registration Number
NCT02840812
Locations
🇨🇳

ZheJiang Medicine, Shaoxing, China

Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function

Phase 1
Completed
Conditions
Liver Dysfunction
Interventions
Drug: Nemonoxacin
First Posted Date
2015-11-13
Last Posted Date
2018-03-30
Lead Sponsor
Zhejiang Medicine Co., Ltd.
Target Recruit Count
20
Registration Number
NCT02604498
Locations
🇨🇳

Huashan Hospital, Fudan University, Shanghai, Shanghai, China

A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP

First Posted Date
2014-07-31
Last Posted Date
2021-10-25
Lead Sponsor
TaiGen Biotechnology Co., Ltd.
Target Recruit Count
598
Registration Number
NCT02205112
Locations
🇨🇳

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

🇨🇳

Taipei Medical University - Shuang Ho Hospital, Taipei, Taiwan

and more 60 locations

Study to Evaluate the Efficacy and Safety of Oral Administration With Nemonoxacin and Levofloxacin in Patients With CAP

Phase 3
Completed
Conditions
Pneumonia
Interventions
Drug: Nemonoxacin
Drug: Levofloxacin
First Posted Date
2012-02-08
Last Posted Date
2013-06-18
Lead Sponsor
TaiGen Biotechnology Co., Ltd.
Target Recruit Count
540
Registration Number
NCT01529476
Locations
🇨🇳

Beijing Union Medical College Hospital, Beijing, China

🇨🇳

China Medical University Hospital, Taichung, Taiwan

🇨🇳

Anzhen Hospital,Beijing Capital Medical University, Anzhen, China

and more 54 locations

Clinical Study on Oral Nemonoxacin Malate Capsules

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Nemonoxacin
First Posted Date
2011-07-15
Last Posted Date
2011-07-15
Lead Sponsor
TaiGen Biotechnology Co., Ltd.
Target Recruit Count
76
Registration Number
NCT01395108
Locations
🇨🇳

Institute of Antibiotics, Huashan Hospital, Fundan University, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy